We are live on ! Find out more
KP

Kiltearn Partners Portfolio holdings

AUM $372M
1-Year Est. Return 18.16%
This Fund
S&P 500
This Quarter Est. Return
+7.89%
1 Year Est. Return
+18.16%
3 Year Est. Return
+34.48%
5 Year Est. Return
+43.43%
10 Year Est. Return
+168.94%
AUM
$2.65B
AUM Growth
-$106M
Cap. Flow
-$277M
Cap. Flow %
-10.46%
Top 10 Hldgs %
57.42%
Holding
27
New
1
Increased
8
Reduced
16
Closed
2

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$39.6M
2
NLSN
Nielsen Holdings plc
NLSN
+$15.2M
3
MS icon
Morgan Stanley
MS
+$13.4M
4
XOM icon
ExxonMobil
XOM
+$13.2M
5
WFC icon
Wells Fargo
WFC
+$12.7M

Sector Composition

Rank Sector Weight
1 Financials 46.83%
2 Energy 16.02%
3 Healthcare 10.84%
4 Consumer Discretionary 7.96%
5 Communication Services 6.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
C icon
1
Citigroup
C
$215B
$212M 8.02%
2,657,633
-296,700
-10% -$21.9M
GS icon
2
Goldman Sachs
GS
$294B
$212M 8.01%
921,823
-102,000
-10% -$22.1M
SLB icon
3
SLB Ltd
SLB
$73.6B
$203M 7.67%
5,052,984
+79,628
+2% +$2.84M
XOM icon
4
ExxonMobil
XOM
$649B
$144M 5.44%
2,064,325
+190,300
+10% +$13.2M
BEN icon
5
Franklin Resources
BEN
$16.9B
$138M 5.21%
5,307,694
-579,200
-10% -$15.7M
HOG icon
6
Harley-Davidson
HOG
$2.65B
$129M 4.88%
3,472,177
-231,600
-6% -$8.62M
WFC icon
7
Wells Fargo
WFC
$256B
$124M 4.7%
2,312,458
+242,700
+12% +$12.7M
AMG icon
8
Affiliated Managers Group
AMG
$9.7B
$124M 4.7%
1,467,130
+16,000
+1% +$1.31M
CVS icon
9
CVS Health
CVS
$136B
$119M 4.48%
1,595,509
-74,700
-4% -$5.25M
IVZ icon
10
Invesco
IVZ
$12.5B
$114M 4.31%
6,345,677
-696,500
-10% -$11.9M
MS icon
11
Morgan Stanley
MS
$324B
$107M 4.03%
2,084,866
+283,960
+16% +$13.4M
STT icon
12
State Street
STT
$49B
$104M 3.95%
1,320,400
-382,500
-22% -$26.9M
AXP icon
13
American Express
AXP
$225B
$104M 3.92%
832,970
-92,700
-10% -$11.1M
NLSN
14
DELISTED
Nielsen Holdings plc
NLSN
$94.4M 3.57%
4,652,048
+750,300
+19% +$15.2M
OMC icon
15
Omnicom Group
OMC
$23.8B
$85.9M 3.24%
1,059,719
+17,400
+2% +$1.36M
KT icon
16
KT
KT
$8.83B
$82.9M 3.13%
7,149,125
-80,300
-1% -$915K
AZO icon
17
AutoZone
AZO
$51.6B
$81.5M 3.08%
68,409
-9,611
-12% -$11.1M
BKR icon
18
Baker Hughes
BKR
$59.6B
$76.7M 2.9%
2,994,400
-332,000
-10% -$7.55M
ZBH icon
19
Zimmer Biomet
ZBH
$18.7B
$72.5M 2.74%
498,932
-54,590
-10% -$7.54M
KMB icon
20
Kimberly-Clark
KMB
$37.5B
$68M 2.57%
494,199
-54,000
-10% -$7.3M
JCI icon
21
Johnson Controls International
JCI
$85.2B
$58.7M 2.22%
1,442,300
-692,700
-32% -$29.2M
LYB icon
22
LyondellBasell Industries
LYB
$19.6B
$57.3M 2.16%
606,000
+10,300
+2% +$944K
BIIB icon
23
Biogen
BIIB
$30.6B
$56.4M 2.13%
190,200
-21,000
-10% -$5.83M
GILD icon
24
Gilead Sciences
GILD
$167B
$39.6M 1.49%
+608,700
New +$39.6M
UNFI icon
25
United Natural Foods
UNFI
$3.07B
$38.5M 1.46%
4,398,639
-444,451
-9% -$3.58M

Similar funds

Kiltearn Partners's Q4 2019 Portfolio in Review

As of Q4 2019, Kiltearn Partners held 27 positions worth $2.65B, down 3.9% from $2.75B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Kiltearn Partners withdrew a net $277M in Q4 2019, closing 2 positions and reducing 16 holdings. Its most notable exit was McKesson, an estimated $152M position sold in full.

By sector, the portfolio is most concentrated in Financials at 47% of assets, up from 44% a quarter earlier, followed by Energy and Healthcare.

Against the trend, Kiltearn Partners opened a new position in Gilead Sciences worth $39.6M.

  • Kiltearn Partners's largest Q4 2019 buy was Gilead Sciences: 608,700 shares worth $39.6M.
  • Kiltearn Partners added most to Nielsen Holdings plc in Q4 2019, an estimated $15.2M increase.
  • Kiltearn Partners's biggest Q4 2019 reduction was Johnson Controls International, cutting an estimated $29.2M.
  • Kiltearn Partners fully exited McKesson in Q4 2019, selling an estimated $152M.
  • Kiltearn Partners's ten largest holdings make up 57% of its $2.65B portfolio in Q4 2019.
  • Kiltearn Partners opened 1 new position and closed 2 in Q4 2019.
  • Kiltearn Partners's portfolio value fell 3.9% quarter-over-quarter to $2.65B.

Based on Kiltearn Partners's 13F filing for Q4 2019, filed 13 Feb 2020.